Department of Pulmonology and Lung Cancer, Wroclaw University of Medicine, ul. Grabiszyńska 105, Wrocław, Poland.
Cancer Genomics Proteomics. 2010 Nov-Dec;7(6):331-5.
Survivin and p53 are proteins that take part in cell cycle and apoptosis regulation. The biological function of survivin is essential for its oncogenic potential. The p53 protein is known to be a guardian of the genome and alterations in its structure enhance resistance to apoptosis. The aim of this study was to detect survivin and p53 expression in 74 non-small cell lung cancer in relation to basic clinicopathological data including the two-year prognosis.
A total of 74 patients with non-small cell lung cancer were recruited into the study. Marker presence was revealed using immunohistochemical methods on paraffin-embedded tissue.
The presence of p53 was visible in 52.7% of cases and its expression did not correlate with clinicopathological data. Survivin immunoreactivity was detected in 52.7% of all study cases and was statistically more often found in lung adenocarcinomas than in squamous cell subtype of lung cancer (67% and 37% respectively, p=0.03). Larger tumours, cancer with lymph node metastases and more advanced tumours according to TNM status showed higher incidence of survivin expression, but differences did not reach statistical significance. The survivin immunoreactivity did not correlate with the two-year survival.
P53 protein expression did not appear to be a clinically important tumour marker. The clearly visible trend to more frequent survivin presence in more advanced non-small cell lung tumours needs further evaluation. The statistically significant difference in survivin immunoreactivity between two major pathological types of non-small cell lung cancer may be important for better selection of patients for specific biological therapy based on apoptosis regulation.
Survivin 和 p53 是参与细胞周期和细胞凋亡调控的蛋白质。Survivin 的生物学功能对于其致癌潜能至关重要。p53 蛋白被认为是基因组的守护者，其结构的改变增强了对细胞凋亡的抵抗。本研究旨在检测 74 例非小细胞肺癌中 survivin 和 p53 的表达与包括两年预后在内的基本临床病理数据的关系。
共招募了 74 例非小细胞肺癌患者入组本研究。使用免疫组织化学方法在石蜡包埋组织上显示标志物的存在。
p53 的存在可见于 52.7%的病例，其表达与临床病理数据无关。所有研究病例中均检测到 survivin 免疫反应性，在肺腺癌中明显比在鳞状细胞肺癌亚型中更常见（分别为 67%和 37%，p=0.03）。更大的肿瘤、有淋巴结转移的癌症和根据 TNM 分期更晚期的肿瘤显示出更高的 survivin 表达发生率，但差异无统计学意义。survivin 免疫反应性与两年生存率无关。
p53 蛋白表达似乎不是一个重要的临床肿瘤标志物。在更晚期的非小细胞肺癌肿瘤中，更频繁地出现 survivin 的明显趋势需要进一步评估。在非小细胞肺癌的两种主要病理类型之间，survivin 免疫反应性的统计学显著差异可能对基于细胞凋亡调控的特定生物治疗患者的更好选择很重要。
